ADVERTISEMENTs
.png)
Skye Bioscience appoints Puneet S. Arora as chief medical officer
His appointment is expected to significantly bolster Skye's efforts to expand its pipeline in the metabolic health space.
Dr. Puneet Arora / Image- LinkedIn
Skye Bioscience, a California-based clinical-stage biopharmaceutical company, has announced the appointment of Indian American physician-scientist Puneet S. Arora as chief medical officer (CMO).
Arora joins Skye at a critical juncture as it prepares to initiate its Phase 2 CBeyond clinical trial for nimacimab, a differentiated CB1 inhibitor for the treatment of obesity.
"We are thrilled to welcome Dr. Puneet Arora as the chief medical officer at Skye at this pivotal moment in our journey," said Punit Dhillon, Skye's CEO and chair. "Dr. Arora is well-regarded in the industry and brings extensive experience in designing and executing clinical trials across multiple therapeutic areas. His expertise in metabolic diseases, such as obesity, will be invaluable as we advance treatments to significantly improve health outcomes."
An executive leader with over 15 years of experience in clinical development, regulatory submissions, and medical affairs, Arora previously served as CMO at Lassen Therapeutics, where he played a key role in advancing their lead molecule into clinical trials and raising Series B funding.
His career also includes leadership roles at Principia Biopharma, a Sanofi company, where he led clinical development strategy across various programs, and at Genentech Research and Early Development, where he directed global clinical programs in metabolism and cardiovascular diseases.
Expressing his enthusiasm for the role, Arora stated, "I have been following Skye’s progress for the past year and believe nimacimab has unique potential as an obesity therapeutic. CB1 inhibition has broad evidence that its distinct attributes could potentially provide longer-term, healthier outcomes for those seeking weight loss. Within the class, nimacimab is differentiated not only by its positive safety and tolerability profile but also by its potential to meaningfully impact the lives of patients struggling with obesity."
Arora completed his MBBS in Medicine at the All India Institute of Medical Sciences in 1996, followed by a residency in Internal Medicine at Southern Illinois University School of Medicine in 1999.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
E Paper
ADVERTISEMENT
.jpg)
Video
.jpg)
.jpg)
.jpg)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login